Sailong Pharmaceutical Group Co., Ltd.

To evaluate the efficacy and safety of dexlansoprazole for injection in the treatment of peptic ulcer bleeding, using lansoprazole for injection as a control.

To investigate the pharmacokinetic characteristics of a single injection of voriconazole for injection (test preparation T, strength: 200 mg) produced by Hunan Sailon Pharmaceutical Co., Ltd. and a single injection of voriconazole for injection certified by Pfizer Europe MA EEIG (reference preparation R, trade name: Vfend®, strength: 200 mg) in healthy subjects under fasting conditions, evaluate the bioequivalence and safety of the two preparations, and provide a basis for the registration application of the test preparation.

The pharmacokinetic characteristics of the test preparation apixaban tablets (specification: 2.5 mg, produced by Hunan Sailon Pharmaceutical Co., Ltd.) and the reference preparation apixaban tablets (Aleto®, specification: 2.5 mg; produced by Bristol-Myers Squibb Manufacturing Company) were studied in healthy subjects after a single oral dose in the fasting and fed states, and the bioequivalence of the two preparations after oral administration in the fasting and fed states was evaluated.